Tandem Diabetes: ADA Presentations Reaffirm Control-IQ Excellent Performance

|
About: Tandem Diabetes Care, Inc. (TNDM)
by: Leonard Yaffe
This article is exclusive for subscribers.
Leonard Yaffe
Growth, Hedge Fund Manager, healthcare, Biotech
Summary

I attended the ADA this weekend, including a Sunday afternoon session that had clinicians presenting data on Control-IQ in adults and children.

Both trial results demonstrated impressive glucose control, time in range, closed loop use and, importantly, user satisfaction.

The introduction of t:slim X2 with Control IQ should put Tandem in the technological lead regarding insulin pumps.  Both Medtronic and Tandem have advanced the glucose control of diabetic patients.

Importantly, I do not expect Medtronic's next system, the 780G, to be available in the U.S. market before 2021. This should give Tandem time to establish Control-IQ, slated for a Q4 2019 introduction.

Data presented by two studies, one NIH funded and one performed in France, supported the safety and efficacy of the Tandem (TNDM) t:slim X2 with Control-IQ. In a 6 month study in adults,